The CEO of SpectraCure increases his shareholding through MK Capital

SpectraCure CEO Masoud Khayyami has, through his company MK Capital Invest, on November 8th bought 10 000 shares in SpectraCure. The shares were purchased at a rate of SEK 8.20 per share, corresponding to a transaction of SEK 82 000. The transaction was made on Aktietorget, according to the Financial Supervisory Authority (sv Finansinspektionen) transparency register. Prior to the acquisition, Masoud Khayyami and MK Capital Invest AB jointly owned 11 472 677 number of shares corresponding to 20.14% of the capital and votes, and after the acquisition, Masoud Khayyami and MK Capital Invest AB jointly owns 11 482 677 number of shares corresponding to 20.15% of Capital and votes.  

For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.

Read as PDF.

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope